title: [Colorectal cancer: ten years of illusion of progress but advances are on the horizon].
abstract: Recent years have basically been marked by a modest progress in digestive oncology. Biologic drugs such as anti-EGFR and antiangiogenic antibodies have improved the overall survival of patients with advanced colorectal cancer for a few months, but did not alter adjuvant treatment paradigms after curative resection of a locally advanced colon cancer or of liver metastases. With the exception of the RAS gene mutations, predictive of lack of effectiveness to anti-EGFR antibodies, our knowledge of colon cancer tumor biology has hardly evolved. Long-awaited novelties come rather from fundamental discoveries about the different genomic subtypes of colorectal cancer and new immunotherapy approaches which both announce hopefully real giant leaps in the near future.
authors.forename: L
authors.initials: L
authors.lastname: Shaza
authors.forename: N
authors.initials: N
authors.lastname: Charette
authors.forename: A
authors.initials: A
authors.lastname: Hendlisz
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D006801:Humans; D007167:Immunotherapy / Q000639:trends; D008495:Medical Oncology / Q000639:trends*; D035703:Therapies, Investigational / Q000523:psychology / Q000639:trends